On October 3, 2019, Heron Therapeutics, Inc. (the "Company") reported that it has entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters identified in Schedule A thereto (the "Underwriters"), pursuant to which the Company (i) agreed to issue and sell an aggregate of 8,571,429 shares of its common stock (the "Shares") to the Underwriters and (ii) granted the Underwriters an option for 30 days to purchase up to an additional 1,285,714 shares of its common stock that may be sold upon the exercise of such option by the Underwriters (the "Offering") (Filing, Heron Therapeutics, OCT 8, 2019, View Source [SID1234540946]). The Shares were sold at a public offering price of $17.50 per Share and, except with respect to the Shares sold to Tang Capital Partners, LP ("TCP"), were purchased by the Underwriters from us at a price of $16.45 per Share. TCP, an affiliate of Kevin Tang, the Chairman of the Board of Directors of the Company, agreed to purchase 285,714 of the Shares in the Offering at the public offering price. The Underwriters did not receive any underwriting discounts or commissions with respect to the sale of Shares to TCP.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

We estimate that the net proceeds we will receive from the Offering, excluding the proceeds from the additional 1,285,714 shares of common stock that may be purchased by the Underwriters following the exercise of their option, will be approximately $141.1 million, after deducting the Underwriters’ discounts and commissions and estimated offering expenses payable by us.

The Offering was made pursuant to the Company’s automatically effective registration statement on Form S-3 (Registration No. 333-219172), which was previously filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "Securities Act").

The Offering closed on October 8, 2019. In the Underwriting Agreement, the Company agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments that the Underwriters may be required to make because of such liabilities. A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.

On October 8, 2019 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported a poster presentation at the upcoming Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology, being held from October 15 – 17, 2019 in London, United Kingdom (Press release, Cellectar Biosciences, OCT 8, 2019, View Source [SID1234540943]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Details

Poster Title: Phospholipid lipid ether delivery vehicle shows specificity for a broad range of tumor cells and provides a novel and improved approach for targeted therapy.
Date: Tuesday, October 15, 2019, 9 a.m. – 5 p.m.
Location: Leonardo Royal Hotel Tower Bridge, London, UK

A copy of the presentation materials can be accessed on the Posters and Publications section of the Cellectar website once the presentation concludes.

On October 8, 2019 The Excelera Network was selected by Karyopharm Therapeutics, Inc., to be in the limited distribution network for XPOVIO (selinexor), which was approved as a treatment for patients with multiple myeloma by the U.S. Food and Drug Administration (FDA) (Press release, Karyopharm, OCT 8, 2019, View Source [SID1234540124]). The Excelera Network, which includes over 20 health systems, 500 hospitals and 100K physicians, received immediate access to the drug upon FDA approval in July.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to be included in Karyopharm’s limited distribution network for XPOVIO," said Rebecca Rand, vice president of manufacturer relations at Excelera. "XPOVIO offers adults with multiple myeloma who have exhausted other options with a novel therapy option to treat their disease. We are committed to providing our health systems with rapid access to innovative therapies such as XPOVIO, as well as the necessary clinical knowledge to effectively deliver these therapies to complex patients in an integrated care model."

XPOVIO is a nuclear export inhibitor that has been approved for use in combination with the corticosteroid dexamethasone, for treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Approved by the FDA on July 3, 2019, XPOVIO was granted both Fast Track and Orphan Drug designation and received accelerated approval, which enables the FDA to approve drugs for serious conditions and to fill an unmet medical need.

"We are delighted to be working with Excelera to help meet the growing demand for XPOVIO in the U.S.," said Kirk Schamp, vice president of market access at Karyopharm. "Excelera has proven capabilities enhancing patient access to novel medicines and we look forward to working together to serve the needs of physicians and their patients battling multiple myeloma."

Multiple myeloma is a cancer that forms in plasma cells. Abnormal plasma cells accumulate in the bone marrow, where they crowd out healthy blood cells and form tumors in many bones of the body. Multiple myeloma is the second most common cancer of the blood in the U.S., with more than 32,000 new cases each year and over 130,000 patients currently living with the disease.

To learn more about Excelera or becoming a member of the Excelera Network, contact us at View Source

On October 8, 2019 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, reported that it will announce its third-quarter 2019 financial results on Friday, November 1 before the market opens (Press release, AbbVie, OCT 8, 2019, View Source [SID1234540123]). AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern). It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 8, 2019 ImaginAb Inc., a clinical-stage immuno-oncology imaging company, reported publication of its data in leading peer-reviewed medical radiology publication, The Journal of Nuclear Medicine (JNM) (Press release, ImaginAb, OCT 8, 2019, View Source [SID1234540122]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The paper entitled "First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targetingi" reports the results from a first in-vivo clinical study to assess the safety, tolerability, and efficacy of ImaginAb’s lead product, CD8 tracer, 89Zr-Df-IAB22M2C, in visualizing the immune system.

The data from the Phase I trial reported in the paper demonstrated 89Zr-Df-IAB22M2C was well tolerated with no immediate or delayed side effects observed. In conclusion, the study found 89Zr- Df-IAB22M2C imaging to be safe and with favorable kinetics for early imaging. The biodistribution suggested successful targeting of CD8+ T cell-rich tissues. The observed targeting of tumor lesions suggests this may be informative for CD8+ T cell accumulation within tumors.

Lead author of the study, Neeta Pandit-Taskar, MD, Nuclear Medicine Physician at Memorial Sloan Kettering Cancer Center, said: "This novel imaging agent has the potential to non-invasively assess the presence of CD8 T cells in patients’ tumors and results of this initial assessment are encouraging. With more research, this technology may ultimately serve a critical role as a biomarker of immunotherapy outcome and inform clinical trials of novel immunotherapies that act mechanistically through the presence of CD8 T cells."

Ian Wilson, CEO of ImaginAb, added: "We are delighted that this paper has been published in The Journal of Nuclear Medicine, a highly regarded publication in the field of imaging and radiology. Our pioneering clinical trial involving patients at leading cancer therapy centers, Memorial Sloan Kettering Cancer Center, University of Pennsylvania, and Honor Health, are furthering ImaginAb’s goal to provide target-specific imaging agents to predict, inform, monitor and enable treatment of cancer disease more effectively."

ImaginAb’s lead product, CD8 tracer 89Zr-Df-IAB22M2C, is a first in class imaging agent that visualizes the immune system using non-invasive, whole-body in vivo PET imaging of CD8 T cells. Currently, in Phase II multi-center clinical trials at world-renowned imaging and cancer centers in North America, the 89Zr-Df-IAB22M2C immunoPET agent detects and visualizes CD8 T cells using ImaginAb’s ‘minibody’ technology. This provides highly-specific, quantitative assessment of the immunological status of individual cancer lesions within a patient, potentially enabling treatment to be tailored quickly and specifically to the needs of that patient.

Publication details: doi: 10.2967/jnumed.119.229781

For further information, please contact:

ImaginAb
Ian Wilson, CEO
Salli Walker, External Partnership Manager
Email: [email protected]
Phone: +1 310 645 1211

Optimum Strategic Communications
Mary Clark, Supriya Mathur
Email: [email protected]
Phone: +44 20 3950 9144